A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jonathan Lu, MD
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Study Director - Medical Director
Merck Sharp & Dohme LLC
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the University of Arizona
Tucson, Arizona, United States
- Brigham and Women'S Hospital
Boston, Massachusetts, United States
- Mayo Clinic
Rochester, Minnesota, United States
- University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Apr 2019
- Primary completion
- 21 Dec 2021
- Completion
- 22 Mar 2022
- Last update posted
- 27 Aug 2024
- Registered enrollment
- 21
- Registry id
- NCT03738150
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.